Search results
Showing 1 to 15 of 16 results for fondaparinux
This guideline covers assessing and reducing the risk of venous thromboembolism (VTE or blood clots, including deep vein thrombosis and pulmonary embolism) in people aged 16 and over in hospital. It aims to help healthcare professionals identify people most at risk and describes interventions that can be used to reduce the risk of VTE.
Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing venous thromboembolism after hip or knee replacement surgery in adults.
View recommendations for TA157Show all sections
This guideline covers the early and longer-term (rehabilitation) management of acute coronary syndromes. These include ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina. The guideline aims to improve survival and quality of life for people who have a heart attack or unstable angina.
Apixaban for preventing venous thromboembolism after hip or knee replacement surgery (TA245)
Evidence-based recommendations on apixaban (Eliquis) for preventing venous thromboembolism after hip or knee replacement in adults.
View recommendations for TA245Show all sections
Rivaroxaban for preventing venous thromboembolism after hip or knee replacement surgery (TA170)
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing venous thromboembolism after hip or knee replacement in adults.
View recommendations for TA170Show all sections
Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)
Evidence-based recommendations on rivaroxaban (Xarelto) for treating pulmonary embolism and for preventing a further deep vein thrombosis or pulmonary embolism in adults.
directly comparing apixaban with rivaroxaban, dabigatran etexilate and fondaparinux would strengthen the evidence base for these...
Evidence-based recommendations on apixaban (Eliquis) for treating and preventing recurrent deep vein thrombosis or pulmonary embolism in adults.
unfractionated heparin (UFH)• fondaparinux sodium• direct-acting anticoagulant• vitamin K antagonists C: standard-dose:• LMWH UFH•...
standard-dose:• low molecular weight heparins• unfractionated heparins• fondaparinux sodium• direct-acting anticoagulant• vitamin K...
Current evidence supports a recommendation for prophylaxis with LMWH or fondaparinux. Bothinvolve a subcutaneous injection for 28 days...
for outpatient treatments) with establishedtreatments such as LMWH or fondaparinux were identified in the evidence review. The...
Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (NG158)
This guideline covers diagnosing and managing venous thromboembolic diseases in adults. It aims to support rapid diagnosis and effective treatment for people who develop deep vein thrombosis (DVT) or pulmonary embolism (PE). It also covers testing for conditions that can make a DVT or PE more likely, such as thrombophilia (a blood clotting disorder) and cancer. It does not cover pregnant women.
Ultrasound‑enhanced, catheter‑directed thrombolysis for pulmonary embolism (IPG524)
Evidence-based recommendations on ultrasound enhanced catheter-directed thrombolysis for pulmonary embolism. This involves using ultrasound waves and a drug to break up the clot.
Evidence-based recommendations on dabigatran etexilate (Pradaxa) for treating and preventing deep vein thrombosis and pulmonary embolism in adults.